Ganna Blazhenets
Overview
Explore the profile of Ganna Blazhenets including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
534
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harloff A, Blazhenets G, Fostitsch J, Strecker C, Dersch R, Mayerhofer E, et al.
EJNMMI Res
. 2024 Nov;
14(1):116.
PMID: 39572471
Background: Symptoms in acute cerebral sinus venous thrombosis (CSVT) are highly variable, ranging from headaches to fatal stroke, and the basis for this high inter-individual variability is poorly understood. The...
2.
Frings L, Blazhenets G, Brumberg J, Rau A, Urbach H, Meyer P
Sci Rep
. 2024 Aug;
14(1):20030.
PMID: 39198541
Cerebral atrophy is a key finding in patients with dementia and usually determined on MRI. We tested whether cerebral atrophy can be imaged with FDG PET by applying deformation-based morphometry...
3.
Zerweck L, Roder C, Blazhenets G, Martus P, Thurow J, Haas P, et al.
Diagnostics (Basel)
. 2024 Jul;
14(13).
PMID: 39001327
Before revascularization, moyamoya patients require hemodynamic evaluation. In this study, we evaluated the scoring system , (PIRAMID). We also devised a new scoring system, (MARS-MMA), and compared the scoring systems...
4.
Brumberg J, Blazhenets G, Buhler S, Fostitsch J, Rijntjes M, Ma Y, et al.
Ann Neurol
. 2024 Jun;
96(3):539-550.
PMID: 38888141
Objective: Patients with Lewy body diseases have an increased risk of dementia, which is a significant predictor for survival. Posterior cortical hypometabolism on [F]fluorodeoxyglucose positron emission tomography (PET) precedes the...
5.
Miguel Telega L, Berti R, Blazhenets G, Domogalla L, Steinacker N, Omrane M, et al.
Prog Neuropsychopharmacol Biol Psychiatry
. 2024 Apr;
133:111013.
PMID: 38636702
Background: Reserpine (RES), a Vesicular Monoamine Transporter 2 (VMAT) inhibitor agent, has been used in preclinical research for many years to create animal models for depression and to test experimental...
6.
Sajonz B, Frommer M, Reisert M, Blazhenets G, Schroter N, Rau A, et al.
Neuroimage Clin
. 2024 Feb;
41:103576.
PMID: 38367597
Background: Thalamic deep brain stimulation (DBS) is an efficacious treatment for drug-resistant essential tremor (ET) and the dentato-rubro-thalamic tract (DRT) constitutes an important target structure. However, up to 40% of...
7.
Rau A, Schroter N, Blazhenets G, Maurer C, Urbach H, Meyer P, et al.
Alzheimers Res Ther
. 2023 Nov;
15(1):202.
PMID: 37980531
Identification of patients with idiopathic normal pressure hydrocephalus (iNPH) in a collective with suspected neurodegenerative disease is essential. This study aimed to determine the metabolic spatial covariance pattern of iNPH...
8.
Blazhenets G, Soleimani-Meigooni D, Thomas W, Mundada N, Brendel M, Vento S, et al.
J Nucl Med
. 2023 Nov;
64(12):1980-1989.
PMID: 37918868
Tau PET has enabled the visualization of paired helical filaments of 3 or 4 C-terminal repeat tau in Alzheimer disease (AD), but its ability to detect aggregated tau in frontotemporal...
9.
Schroter N, Bormann T, Rijntjes M, Blazhenets G, Berti R, Sajonz B, et al.
Mov Disord Clin Pract
. 2023 Jul;
10(7):1066-1073.
PMID: 37476309
Background: Cognitive deficits considerably contribute to the patient's burden in Parkinson's disease (PD). While cognitive decline is linked to neuronal dysfunction, the additional role of white matter lesions (WML) is...
10.
Schroter N, Blazhenets G, Meyer P, Rijntjes M, Brumberg J
Mov Disord Clin Pract
. 2023 Mar;
10(3):531-532.
PMID: 36949786
No abstract available.